2 weeks Ago By ABMN Staff
Geron Co. ( NASDAQ:GERN – Get Free Report ) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 71,510,000 shares, a growth of 6.
5% from the August 31st total of 67,140,000 shares. Based on an average daily trading volume, of 9,480,000 shares, the days-to-cover ratio is presently 7.5 days.
Wall Street Analysts Forecast Growth Several research analysts have weighed in on GERN shares. Leerink Partners assumed coverage on Geron in a report on Monday, September 9th. They set an “outperform” rating and a $7.
00 target price on the stock. Stifel Nicolaus boosted their price objective on Geron from $6.00 to $7.
00 and gave the company a “buy” rating in a research report on Monday, June 10th. Barclays began coverage on shares of Geron in a report on Monday, June 10th. They set an “overweight” rating and a $9.
00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, August 9th.
Finally, Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.
06. Read Our Latest Stock Report on GERN Insider Transactions at Geron Institutional Inflows and Outflows Several large investors have recently bought and sold shares of GERN. Vanguard Group Inc.
raised its stake in shares of Geron by 4.6% during the 1st quarter. Vanguard Group Inc.
now owns 29,869,287 shares of the biopharmaceutical company’s stock worth $98,569,000 after purchasing an additional 1,304,713 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in Geron during the second quarter worth $106,185,000.
Farallon Capital Management LLC raised its position in Geron by 124.6% during the second quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after acquiring an additional 9,342,000 shares in the last quarter.
Charles Schwab Investment Management Inc. lifted its stake in Geron by 5.7% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 3,842,500 shares of the biopharmaceutical company’s stock valued at $8,108,000 after acquiring an additional 208,170 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in Geron in the first quarter valued at $8,250,000.
73.71% of the stock is owned by institutional investors and hedge funds. Geron Stock Down 2.
9 % Shares of GERN stock traded down $0.13 during trading on Tuesday, reaching $4.41.
The company’s stock had a trading volume of 7,575,236 shares, compared to its average volume of 10,778,605. Geron has a one year low of $1.64 and a one year high of $5.
34. The business has a fifty day moving average price of $4.53 and a 200-day moving average price of $4.
16. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -12.
60 and a beta of 0.50. The company has a quick ratio of 3.
60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.
Geron ( NASDAQ:GERN – Get Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.
10). The firm had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $0.
34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.
79%. The company’s revenue for the quarter was up 2941.4% on a year-over-year basis.
During the same period in the previous year, the firm posted ($0.09) EPS. Analysts anticipate that Geron will post -0.
34 earnings per share for the current year. Geron Company Profile ( Get Free Report ) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter ..
